EMAIL THIS PAGE TO A FRIEND

Expert opinion on drug delivery

Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis.


PMID 25078031

Abstract

The primary aim of present work was to develop effective combination drug therapy for topical treatment of psoriasis. Betamethasone dipropionate and calcipotriol loaded solid lipid nanoparticles (CT-BD-SLNs) were prepared by hot melt high shear homogenization technique, which were then incorporated in Carbopol gel matrix. The anti-psoriatic potential was tested by sequential in vitro (skin permeation and dermal distribution, anti-proliferative effect in HaCaT cells) and in vivo (Draize patch irritation, transepidermal water loss (TEWL) and anti-psoriatic mouse tail studies) experiments. A negligible amount in receptor compartment, yet confined distribution of drugs to epidermal and dermal region of skin was observed in case of SLNs, which is essential for safe and effective anti-psoriatic therapy. Draize patch test and TEWL demonstrated negligible skin irritation and better skin tolerability of SLNs. The in vitro HaCaT cell line study demonstrated that SLNs delayed the abrupt growth of keratinocytes, while in vivo mouse tail model showed that SLNs gel significantly decreased the epidermal thickness and increased melanocyte count in comparison to commercial Daivobet® ointment. The developed SLNs gel is expected to be potential strategies for treatment of psoriasis and other topical diseases.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

1067704 Betamethasone dipropionate, United States Pharmacopeia (USP) Reference Standard
C28H37FO7
B1040000 Betamethasone dipropionate, European Pharmacopoeia (EP) Reference Standard
C28H37FO7
PHR1399 Betamethasone Dipropionate, Pharmaceutical Secondary Standard; Certified Reference Material
C28H37FO7
77402
Melting Point Standard 69-71°C, analytical standard
C18H36O2
H5501
Methyl 4-hydroxybenzoate, ReagentPlus®, ≥99.0%, crystalline
C8H8O3
H6654
Methyl 4-hydroxybenzoate, BioXtra, ≥99.0% (titration)
C8H8O3
H3647
Methyl 4-hydroxybenzoate, BioReagent, suitable for insect cell culture
C8H8O3
M8911
Methyl 4-hydroxybenzoate, analytical standard
C8H8O3
54752
Methyl 4-hydroxybenzoate, tested according to Ph.Eur.
C8H8O3
W271004
Methyl 4-hydroxybenzoate, ≥99%, FCC
C8H8O3
47889
Methyl Paraben, analytical standard
C8H8O3
M1650000
Methyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard
C8H8O3
PHR1012
Methylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
C8H8O3
1432005
Methylparaben, United States Pharmacopeia (USP) Reference Standard
C8H8O3
P5835
Propyl 4-hydroxybenzoate, BioXtra
C10H12O3
54789
Propyl 4-hydroxybenzoate, tested according to Ph.Eur.
C10H12O3
P53357
Propyl 4-hydroxybenzoate, ≥99%
C10H12O3
W295101
Propyl 4-hydroxybenzoate, ≥99%
C10H12O3
P3650000
Propyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard
C10H12O3
PHR1010
Propylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
C10H12O3
1577008
Propylparaben, United States Pharmacopeia (USP) Reference Standard
C10H12O3
31448
Sodium metabisulfite, puriss. p.a., ACS reagent, reag. Ph. Eur., dry, 98-100.5%
Na2O5S2
08982
Sodium metabisulfite, analytical standard
Na2O5S2
13459
Sodium metabisulfite, puriss., meets analytical specification of Ph. Eur., BP, NF, FCC, E223, dry, 97-100.5%
Na2O5S2
71932
Sodium metabisulfite, tested according to Ph.Eur.
Na2O5S2
S9000
Sodium metabisulfite, ReagentPlus®, ≥99%
Na2O5S2
161519
Sodium metabisulfite, reagent grade, 97%
Na2O5S2
1614396
Sodium metabisulfite, United States Pharmacopeia (USP) Reference Standard
Na2O5S2
799343
Sodium metabisulfite, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Na2O5S2
PHR1434
Sodium Metabisulfite, Pharmaceutical Secondary Standard; Certified Reference Material
Na2O5S2